Er Therapeutics Stock Current Valuation
| PNGM Stock | USD 0.0001 0.00 0.00% |
Valuation analysis of Er Therapeutics helps investors to measure Er Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Er Therapeutics' Total Cashflows From Investing Activities is very stable compared to the past year. As of the 24th of December 2024, Total Cash From Financing Activities is likely to grow to about 110.7 K, while Change In Cash is likely to drop (4.1 K). Fundamental drivers impacting Er Therapeutics' valuation include:
Price Book 143.7 K | Enterprise Value 122.4 K | Enterprise Value Ebitda (0.25) |
Overvalued
Today
Please note that Er Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Er Therapeutics is based on 3 months time horizon. Increasing Er Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the PNGM stock is determined by what a typical buyer is willing to pay for full or partial control of Er Therapeutics. Since Er Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PNGM Stock. However, Er Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 |
The intrinsic value of Er Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Er Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Er Therapeutics helps investors to forecast how PNGM stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Er Therapeutics more accurately as focusing exclusively on Er Therapeutics' fundamentals will not take into account other important factors: Er Therapeutics Company Current Valuation Analysis
Er Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Er Therapeutics Current Valuation | 122.36 K |
Most of Er Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Er Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Er Therapeutics has a Current Valuation of 122.36 K. This is 100.0% lower than that of the Metals & Mining sector and significantly higher than that of the Materials industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
PNGM Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Er Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Er Therapeutics could also be used in its relative valuation, which is a method of valuing Er Therapeutics by comparing valuation metrics of similar companies.Er Therapeutics is currently under evaluation in current valuation category among its peers.
PNGM Fundamentals
| Return On Asset | -0.95 | ||||
| Current Valuation | 122.36 K | ||||
| Shares Outstanding | 58.26 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Book | 143,650 X | ||||
| Net Income | (426.95 K) | ||||
| Cash And Equivalents | 650 | ||||
| Total Debt | 48.49 K | ||||
| Current Ratio | 0.01 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (161.43 K) | ||||
| Beta | 10.4 | ||||
| Market Capitalization | 332.11 K | ||||
| Total Asset | 423.6 K | ||||
| Working Capital | (638 K) | ||||
| Current Asset | 7 K | ||||
| Current Liabilities | 645 K | ||||
| Net Asset | 423.6 K |
About Er Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Er Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Er Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Er Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Er Therapeutics Piotroski F Score and Er Therapeutics Altman Z Score analysis. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.